Latest News and Press Releases
Want to stay updated on the latest news?
-
NEW YORK, Jan. 22, 2015 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS), a leader in the development and manufacturing of cell therapy products and regenerative medicine, today announced the addition...
-
NEW YORK, Jan. 20, 2015 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) a leader in the development and manufacturing of cell therapy products and regenerative medicine, announced today that the State...
-
NEW YORK and SAN DIEGO, Jan. 12, 2015 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS), a leader in the development and manufacturing of cell therapy products and regenerative medicine, and Invetech Pty...
-
NEW YORK, Jan. 5, 2015 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS), a leader in the development and manufacturing of cell therapy products and regenerative medicine, today announced the...
-
NEW YORK, Dec. 15, 2014 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS), a biopharmaceutical company developing novel cell based therapeutics, and Progenitor Cell Therapy, LLC ("PCT"), a NeoStem...
-
ALLENDALE, N.J., Dec. 8, 2014 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a biopharmaceutical company developing novel cell based therapeutics, and its subsidiary,...
-
NEW YORK, Dec. 1, 2014 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a biopharmaceutical company developing novel cell based therapies, announced today that the Company...
-
NEW YORK, Nov. 26, 2014 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS), a biopharmaceutical company developing novel cell based therapeutics, announced today that it will host a Key Opinion Leader...
-
NEW YORK, Nov. 24, 2014 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) announced today that Dr. Robert Preti, the Company's Chief Scientific Officer and President of its subsidiary, Progenitor Cell...
-
NeoStem Provides Further Information Regarding the Design of the Phase 2 PreSERVE AMI Clinical Trial
NEW YORK, Nov. 21, 2014 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS), a biopharmaceutical company developing novel cell based therapeutics, announced on November 17th initial positive data from its...